Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



3 Obamacare-Inspired Investment Opportunities

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Love it or hate it, the Patient Protection and Affordable Care Act -- commonly referred to as Obamacare -- changes the health care landscape. And anytime there are changes, it creates investment opportunities to take advantage of. Here are three areas you should be looking at as Obamacare hits its stride.

Investment opportunity #1: Biosimilars
Before Obamacare, there was a simple pathway for generic-drug makers to develop small molecule drugs, but biologics -- protein-based drugs -- got a free pass. After a biologic went off patent, the only way to get a copycat approved was to go through the standard branded-drug approval process.

Obamacare ordered the Food and Drug Administration to establish a pathway to approve generic versions of biologic drugs, called biosimilars, because it's impossible to make an exact copy of a biologic without knowing the proprietary way the drug is made.

Many of the branded-drug companies -- Amgen, Novartis, and Merck, for instance -- are developing biosimilars, but they're not likely to see a large impact from the biosimilars given their large size.

If you're looking for a larger impact from the development of biosimilars, Momenta Pharmaceuticals (NASDAQ: MNTA  ) is probably your best bet. The company has a partnership with Baxter (NYSE: BAX  ) , which reduces the marketing risk since Baxter has a fairly large footprint, especially in hospitals.

Investment opportunity #2: Orphan drugs
Obamacare has pushed to lower drug costs, especially those purchased through government programs and some eligible health care organizations through the 340B Drug Pricing Program. But orphan drugs that treat rare diseases were excluded from the program.

From the government's perspective, so few patients are on each drug that giving up the discount probably isn't a major hit. And,of course, the orphan drug designation was designed to encourage development of drugs that might not otherwise be developed. Cutting into profits undermines the purpose of the program.

But despite the limited number of patients, there's still money to be made in orphan drugs because drugmakers can charge $200,000 or more per year for the drugs. BioMarin Pharmaceuticals (NASDAQ: BMRN  ) sold $257 million worth of its orphan drug Naglazyme last year, up 14% year over year. Alexion Pharmaceuticals (NASDAQ: ALXN  ) has done even better with Soliris, its drug for paroxysmal nocturnal hemoglobinuria and another orphan disease, surpassing $1 billion last year.

Investment opportunity #3: Banks (no really)
Earlier this year, Wells Fargo (NYSE: WFC  ) said its health savings accounts, or HSA, grew 31% to end 2012 with more than $800 million on deposit. The accounts allow individuals to deposit pre-tax money for future medical expenses. Banks profit from the deposits in the interim.

Obamacare is likely to increase the number of people with high-deductible insurance, especially relatively healthy individuals who don't need low co-pays because they rarely go to the doctor. The HSAs help deaden the blow from potential high out-of-pocket expenses.

It might be a bit of a stretch to consider Wells Fargo an investment opportunity based solely on its potential to increase HSA accounts; other aspects of its banking business are likely to have a greater influence on the stock price than the amount of HSA accounts it has. But the HSAs can bring in new customers, allowing Wells Fargo to cross-sell its other products to the new customer. Come for an HSA, stay for a home loan.

For more information about how Obamacare might affect you and your portfolio check out The Motley Fool's special free report that makes this complex topic easily understandable. Download "Everything You Need to Know About Obamacare" and discover how the law may impact your taxes, health insurance, and investments. Click here for your free copy today.

Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 29, 2013, at 2:34 PM, 2smartforlibs wrote:

    Your right even in down market there is money to be made but lets call this what it is and Obama care isn't something to love

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2513919, ~/Articles/ArticleHandler.aspx, 9/24/2016 6:46:06 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 21 hours ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:00 PM
ALXN $127.22 Down -6.47 -4.84%
Alexion Pharmaceut… CAPS Rating: ****
BAX $47.49 Down -0.71 -1.47%
Baxter CAPS Rating: ****
BMRN $97.40 Down -0.05 -0.05%
BioMarin Pharmaceu… CAPS Rating: ****
MNTA $11.87 Down -0.22 -1.82%
Momenta Pharmaceut… CAPS Rating: ***
WFC $45.74 Up +0.02 +0.04%
Wells Fargo CAPS Rating: ****
AMGN $174.80 Down -0.82 -0.47%
Amgen CAPS Rating: ****
MRK $62.96 Down -0.06 -0.10%
Merck and Co. CAPS Rating: ****